logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Juvenileonset Still Disease

    Medications for Juvenileonset Still Disease

    FiltersReset Filters
    5 results

    • actemra

      (tocilizumab)
      Genentech, Inc.
      Usage: ACTEMRA (tocilizumab) is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis, severe cytokine release syndrome, and COVID-19 in hospitalized adults receiving systemic corticosteroids.

    • avtozma

      (tocilizumab)
      CELLTRION USA, Inc.
      Usage: AVTOZMA® (tocilizumab-anoh) is indicated for adults with moderately to severely active rheumatoid arthritis, giant cell arteritis, and hospitalized adults with COVID-19. It also treats active polyarticular and systemic juvenile idiopathic arthritis in patients aged 2 years and older.

    • tocilizumab-anoh

      (tocilizumab)
      CELLTRION USA, Inc.
      Usage: Tocilizumab-anoh is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular and systemic juvenile idiopathic arthritis (ages 2+), and COVID-19 in hospitalized adults requiring respiratory support while on systemic corticosteroids.

    • tofidence

      (TOCILIZUMAB)
      Biogen Inc.
      Usage: TOFIDENCE™ (tocilizumab-bavi) is indicated for treating moderately to severely active rheumatoid arthritis in adults who have not responded adequately to DMARDs, as well as active polyarticular and systemic juvenile idiopathic arthritis in patients aged 2 years and older.

    • tyenne

      (Tocilizumab-aazg)
      Fresenius Kabi USA, LLC
      Usage: TYENNE® (tocilizumab-aazg) is indicated for treating moderately to severely active rheumatoid arthritis in adults with inadequate response to DMARDs, giant cell arteritis in adults, and active polyarticular or systemic juvenile idiopathic arthritis in patients aged 2 years and older.